Related Experiment Video
Updated: Feb 6, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Sizheng Zhao1, Laura Chadwick1, Eduardo Mysler2
1Department of Musculoskeletal Biology I, Clinical Sciences Centre, Institute of Ageing and Chronic Disease, University of Liverpool, Aintree University Hospital, Longmoor Lane, Liverpool, L9 7AL, UK.
Purpose Of Review:
Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of numerous biosimilar agents. In this article, we recap the evidence from bio-originator trials in rheumatoid arthritis (RA) to provide context for a critical review of biosimilar trial data.
Recent Findings:
Currently, three adalimumab biosimilars are approved in Europe and/or the USA: Amgen's ABP 501 (AMJEVITA/Solymbic), Boehringer Ingelheim's BI 695501 (Cyltezo) and Samsung Bioepis's SB5 (Imraldi). All three agents met their pre-specified equivalence criteria. Subtle differences in adverse events and clinical responses between the reference and biosimilar products were noted. The introduction of adalimumab biosimilars will offer exciting opportunities in improving treatment access and increasing treatment options for RA and other licensed indications. Real-world data will further provide assurances on efficacy as well as safety.
More Related Videos
09:31Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients
Published on: October 16, 2016
06:31Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
Published on: October 6, 2023
Related Concept Videos
Statistical Software for Data Analysis and Clinical Trials
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Drug Products: Biologics, Biosimilars and Interchangeables
Clinical Trials: Overview
Trial and Error and Algorithm